Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Gastroenterology"
DOI: 10.20524/aog.2022.0704
Abstract: The prevalence of nonalcoholic fatty liver disease (NAFLD) is rapidly growing throughout the world. Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, is likely to become the leading cause of cirrhosis and etiology for liver… read more here.
Keywords: advances pharmacologic; emerging advances; cirrhosis; treatment ... See more keywords